“One of the hidden access issues for...

On the Record   “One of the hidden access issues for cell and gene therapies is the path to market in the first place. We are seeing this overcome with a lot of partnerships compared to other biologic products where they can share the burden of risk.”   —Aklilu Tedla, vice president of advanced therapy solutions at Cardinal Health, spoke with Radar on Specialty Pharmacy about the challenges of developing new cell and gene therapies and getting them on the market.

 

Subscribers may read the Radar on Specialty Pharmacy in which this quote appeared online. Learn more about subscribing to AIS Health's publications.